Trovagene launches new genetic test


Nano cap biotech Trovagene (TROV) debuts a KRAS genetic test that utilizes a urine sample instead of blood or tissue. The company offers the test as a service (laboratory-developed test). It detects the seven most common mutations in the KRAS oncogene.

Consensus revenue estimates for 2013 and 2014 are $360K and $4.2M, respectively.

24 mutual funds have positions, up from 11 a year ago.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs